NO20062491L - Benzoksazinderivter og deres anvendelse - Google Patents

Benzoksazinderivter og deres anvendelse

Info

Publication number
NO20062491L
NO20062491L NO20062491A NO20062491A NO20062491L NO 20062491 L NO20062491 L NO 20062491L NO 20062491 A NO20062491 A NO 20062491A NO 20062491 A NO20062491 A NO 20062491A NO 20062491 L NO20062491 L NO 20062491L
Authority
NO
Norway
Prior art keywords
compounds
benzoxazine derivatives
formula
benzoxazine
derivatives
Prior art date
Application number
NO20062491A
Other languages
English (en)
Inventor
Jacob Berger
Robin Douglas Clark
Shu-Hai Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20062491L publication Critical patent/NO20062491L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forbindelser med formel (I):. eller farmasøytisk akseptable salter, solvater eller prodmgs derav, hvor R, R, R,,, R, R,,, X, Y og m er som definert her. Preparater som inneholder disse forbindelsene, anvendelsen av disse forbindelsene for fremstilling av medikamenter, så vel som metoder for fremstilling av forbindelser med formel (I), er også tilveiebrakt.
NO20062491A 2003-12-09 2006-05-31 Benzoksazinderivter og deres anvendelse NO20062491L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52837803P 2003-12-09 2003-12-09
PCT/EP2004/013557 WO2005058847A1 (en) 2003-12-09 2004-11-30 Benzoxazine derivatives and uses thereof

Publications (1)

Publication Number Publication Date
NO20062491L true NO20062491L (no) 2006-09-06

Family

ID=34699863

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062491A NO20062491L (no) 2003-12-09 2006-05-31 Benzoksazinderivter og deres anvendelse

Country Status (21)

Country Link
US (1) US7202241B2 (no)
EP (1) EP1694656B1 (no)
JP (1) JP4527730B2 (no)
KR (1) KR100827915B1 (no)
CN (1) CN100532369C (no)
AR (1) AR046753A1 (no)
AT (1) ATE371653T1 (no)
AU (1) AU2004299201B2 (no)
BR (1) BRPI0416873A (no)
CA (1) CA2547764A1 (no)
CO (1) CO5700768A2 (no)
DE (1) DE602004008668T2 (no)
ES (1) ES2291984T3 (no)
IL (1) IL175817A0 (no)
MY (1) MY145576A (no)
NO (1) NO20062491L (no)
NZ (1) NZ547120A (no)
RU (1) RU2354651C2 (no)
TW (1) TW200522953A (no)
WO (1) WO2005058847A1 (no)
ZA (1) ZA200604725B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
EP1799306B1 (en) * 2004-09-30 2011-02-23 F. Hoffmann-La Roche AG Compositions and methods for treating cognitive disorders
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
CN101448803A (zh) * 2006-03-17 2009-06-03 阿斯利康(瑞典)有限公司 用作5-ht6调节剂的四氢萘
CL2007003044A1 (es) * 2006-10-24 2008-07-04 Wyeth Corp Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros.
WO2011023753A1 (en) * 2009-08-27 2011-03-03 Glaxo Group Limited Benzoxazine derivatives as glycine transport inhibitors
CN101836993B (zh) 2010-05-20 2011-06-22 山东大学 2，3-二氢-3-羟甲基-6-氨基-[1，4]-苯并噁嗪在制备诱导胚胎干细胞向血管内皮细胞分化药物中的应用
CN102060810B (zh) * 2010-12-20 2012-07-04 金坛市爱特生物科技有限公司 一种n-叔丁氧羰基-哌嗪的提纯方法
AU2015222917A1 (en) 2014-02-27 2016-09-15 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
AU2015286049B2 (en) 2014-07-08 2018-03-01 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
WO2016179343A1 (en) 2015-05-05 2016-11-10 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
CN107980042B (zh) 2015-06-11 2021-10-08 莱斯拉公司 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
CN109568321B (zh) * 2019-01-14 2022-02-22 山东轩竹医药科技有限公司 RORγ调节剂
US12698266B2 (en) 2019-12-19 2026-08-04 Casma Therapeutics, Inc. TRPML modulators
TW202220958A (zh) * 2020-08-07 2022-06-01 美商卡司馬療法公司 Ｔｒｐｍｌ調節劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8803419D0 (en) * 1988-02-15 1988-03-16 Erba Carlo Spa 1 4-benzoxazine & 1 4-benzothiazine derivatives & process for their preparation
GB9507203D0 (en) 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
AU732863B2 (en) 1997-04-18 2001-05-03 Smithkline Beecham Plc Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity
EP1175412A1 (en) * 1999-04-28 2002-01-30 Dr. Reddy's Research Foundation Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1255743A1 (en) 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
UA76877C2 (uk) * 2002-05-13 2006-09-15 Ф.Хоффманн-Ля Рош Аг Похідні бензоксазину як 5-нт6 модулятори і їх застосування
PT1562918E (pt) * 2002-11-08 2008-03-12 Hoffmann La Roche Benzoxazinonas substituídas e as suas utilizações

Also Published As

Publication number Publication date
AR046753A1 (es) 2005-12-21
EP1694656B1 (en) 2007-08-29
JP4527730B2 (ja) 2010-08-18
CA2547764A1 (en) 2005-06-30
BRPI0416873A (pt) 2007-02-27
AU2004299201B2 (en) 2009-12-03
JP2007513904A (ja) 2007-05-31
KR20060097758A (ko) 2006-09-15
AU2004299201A1 (en) 2005-06-30
NZ547120A (en) 2009-02-28
MY145576A (en) 2012-02-29
ZA200604725B (en) 2007-12-27
DE602004008668D1 (de) 2007-10-11
KR100827915B1 (ko) 2008-05-07
RU2006124513A (ru) 2008-01-27
IL175817A0 (en) 2006-10-05
CN1890227A (zh) 2007-01-03
US7202241B2 (en) 2007-04-10
EP1694656A1 (en) 2006-08-30
CN100532369C (zh) 2009-08-26
US20050124613A1 (en) 2005-06-09
ES2291984T3 (es) 2008-03-01
ATE371653T1 (de) 2007-09-15
WO2005058847A1 (en) 2005-06-30
TW200522953A (en) 2005-07-16
RU2354651C2 (ru) 2009-05-10
DE602004008668T2 (de) 2008-06-12
CO5700768A2 (es) 2006-11-30

Similar Documents

Publication Publication Date Title
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
NO20066055L (no) Pyridinderivater
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
NO20050828L (no) lndol-3-svovelderivater
NO20045486L (no) Nye forbindelser og deres anvendelse
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
NO20081844L (no) Terapeutiske forbindelser
NO20065904L (no) Terapeutiske forbindelser
NO20055977L (no) Nye benzimidazolderivater
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
NO20061839L (no) Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
NO20040881L (no) Orale antidiabetes midler.
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20065060L (no) Farmasoytiske kombinasjoner inneholdende benzoksazin for behandling av respiratoriske forstyrrelser
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
NO20065880L (no) 3-Amino-l-arylpropylindoler som monoamin-gjenopptagelsesinhibitor
NO20080110L (no) Benzimidazolderivativer som 5-HT6,5-HT24
NO20052730L (no) Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
BRPI0416873A (pt) derivados de benzoxazina e usos dos mesmos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application